Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

Final draft guidance: 2

Final draft guidance (PDF 304 KB)

Committee papers (PDF 2.4 MB)

Public committee slides (PDF 803 KB)

Appeal

British Association of Dermatologists : Final scrutiny letter (MSWord 75 KB)

British Association of Dermatologists : Scrutiny letter (MSWord 84 KB)

British Association of Dermatologists : Response to scrutiny letter (MSWord 203 KB)

British Association of Dermatologists : Appeal letter (MSWord 220 KB)

Incyte : Appeal letter (MSWord 839 KB)

Incyte : Appeal letter (MSWord 839 KB)

Incyte : Final scrutiny letter (MSWord 71 KB)

Incyte : Response to final scrutiny letter (MSWord 821 KB)

Incyte : Response to final scrutiny letter (MSWord 821 KB)

Incyte : Scrutiny letter (MSWord 80 KB)

The Vitiligo Society : Scrutiny letter (MSWord 77 KB)

The Vitiligo Society : Scrutiny letter (MSWord 83 KB)

Vitiligo Support UK : Final scrutiny letter (MSWord 77 KB)

Vitiligo Support UK : Scrutiny letter (MSWord 84 KB)

Vitiligo Support UK : Appeal letter (MSWord 40 KB)

The Vitiligo Society : Appeal letter (MSWord 491 KB)

Final draft guidance

Final draft guidance (PDF 249 KB)

Public committee slides (PDF 780 KB)

Committee papers (PDF 2.96 MB)

Draft guidance

Public committee slides (PDF 1.66 MB)

Draft guidance (PDF version) (PDF 317 KB)

Draft guidance (online commenting)

Committee papers (PDF 8.89 MB)

Final scope (PDF 165 KB)

Final stakeholder list (PDF 156 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 488 KB)

Draft matrix post referral (PDF 155 KB)